<DOC>
	<DOC>NCT00135954</DOC>
	<brief_summary>Patients with idiopathic membranous nephropathy at risk for renal failure can be identified in an early stage by measuring urinary low molecular weight proteins and urinary immunoglobulin G (IgG). This study evaluates the possible benefit of early start of immunosuppressive therapy in these high-risk patients.</brief_summary>
	<brief_title>Treatment of Patients With Idiopathic Membranous Nephropathy</brief_title>
	<detailed_description>Inclusion Criteria: - patients with idiopathic membranous nephropathy - nephrotic syndrome - normal renal function (serum creatinine [Screat] &lt; 1.5 mg/dl) - elevated urinary beta2-microglobulin and IgG Immunosuppressive therapy consisting of: - cyclophosphamide 1.5 mg/kg/day for 12 months - prednisone orally, 0.5 mg/kg on alternate days for 6 months - i.v. methylprednisolone 1000 mg on days 1,2,3, 60,61,62, 120,121,122 Study Groups: - early: immediate start of immunosuppressive therapy at the time patient is identified as high-risk - late: start of therapy after deterioration of renal function (increase of Screat &gt; 25% and Screat &gt; 1.5 mg/dl) Main Outcome Parameters: - serum creatinine - remission of proteinuria - period of nephrotic proteinuria - major side effects: hospitalisations, infections</detailed_description>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Glomerulonephritis, Membranous</mesh_term>
	<mesh_term>Glomerulonephritis</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<criteria>Idiopathic membranous nephropathy Serum creatinine &lt; 1.5 mg/dl Nephrotic syndrome Infection Instable angina Systemic disease Pregnancy Renal vein thrombosis Prior therapy with immunosuppressant agents Liver dysfunction Use of nonsteroidal antiinflammatory drugs (NSAIDs)</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2007</verification_date>
	<keyword>membranous nephropathy</keyword>
	<keyword>cyclophosphamide</keyword>
	<keyword>prednisone</keyword>
</DOC>